Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Dementia01:30

Dementia

144
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
144
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

166
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality.

Molecules (Basel, Switzerland)·2026
Same author

Liquid crystalline mesophase spacing as a quantitative predictor of release kinetics for co-loaded hydrophilic and hydrophobic payloads.

bioRxiv : the preprint server for biology·2026
Same author

Full vibrational spectroscopy for simultaneous mechanical, structural and chemical analysis.

Nature communications·2026
Same author

Formulation and Evaluation of Indomethacin Nanosuspensions Stabilized by Poly(2-oxazine) and Poly(2-oxazoline)-Based Polymers for Solubility Enhancement.

Pharmaceutical research·2026
Same author

Potential of Low-Frequency Raman Spectroscopy for Structural Screening of Lipid-Based Drug Delivery Systems for Poorly Water-Soluble Drugs.

Molecular pharmaceutics·2026
Same author

Unexpected Effect of Digestion Products of Infant Formula in Enhancing the Solubilisation of Tolfenamic Acid During Digestion.

Pharmaceutics·2026

Related Experiment Video

Updated: Jul 28, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K

Drug Discovery and Development Targeting Dementia.

Agnieszka Zagórska1, Anna Czopek1, Monika Fryc1

  • 1Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.

Pharmaceuticals (Basel, Switzerland)
|June 1, 2023
PubMed
Summary

Millions worldwide, especially the elderly, are affected by dementia, a neurodegenerative disease with no current treatment. This review explores current drug discovery, including small molecules and nanotechnology, to target dementia effectively.

Keywords:
dementiadrug discovery and developmentnanocarriers

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.9K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.0K

Related Experiment Videos

Last Updated: Jul 28, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.9K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Dementia impacts millions globally, primarily the elderly, with no effective treatments available.
  • Neurodegenerative diseases are the most common cause of dementia.
  • There is a critical need for novel therapeutic strategies.

Purpose of the Study:

  • To review the current landscape of drug discovery and development for dementia.
  • To highlight emerging therapeutic approaches and their clinical trial status.
  • To explore the potential of nanotechnology in dementia management.

Main Methods:

  • Comprehensive literature review of drug discovery strategies for dementia.
  • Analysis of small molecules, drug repurposing, and phosphodiesterase inhibitors.
  • Examination of clinical trial data for dementia therapeutics.
  • Assessment of multi-target-directed ligands and disease-modifying therapies.
  • Evaluation of nanotechnology applications in dementia.

Main Results:

  • Several drug discovery avenues are under investigation, including small molecules and repurposed drugs.
  • Phosphodiesterase inhibitors and multi-target-directed ligands show promise.
  • Clinical trials are evaluating the efficacy of various molecular approaches.
  • Disease-modifying therapies are a key focus in dementia research.
  • Nanotechnology presents novel possibilities for dementia management.

Conclusions:

  • Despite challenges, significant progress is being made in dementia drug discovery.
  • A multi-faceted approach combining various therapeutic strategies is essential.
  • Further research and clinical trials are crucial to developing effective dementia treatments.
  • Nanotechnology offers a promising future direction for dementia therapeutics.